Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.52 |
| ▸ | FNTB | P49356 | 14/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564884 | 1.00 | FNTA (0.52) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7571079 | 1.00 | FNTA (0.52) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| Cyclopropane SCHEMBL7680538 | 0.99 | FNTA (0.51) | FNTAFNTBPGGT1BSIGMAR1KMT2A | |
| SCHEMBL7678882 | 0.91 | FNTA (0.51) | FNTAFNTBPGGT1BSIGMAR1 | |
| SCHEMBL7677003 | 0.89 | FNTA (0.43) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7677725 | 0.89 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL7680592 | 0.87 | FNTA (0.44) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7678961 | 0.86 | FNTA (0.53) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7677229 | 0.85 | FNTA (0.43) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL8195311 | 0.85 | FNTA (0.41) | FNTAFNTBPGGT1BSIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002079147-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0021772-B1 | METHOD OF PREPARING 2-OXO- AND 2-UNSUBSTITUTED-HEXAHYDROAZEPINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-01-02 | — | — | EP | disclosed |
| EP-0003253-B1 | HEXAHYDROAZEPINE, PIPERIDINE AND PYRROLIDINE DERIVATIVES AND PROCESSES FOR MAKING AND USING THEM | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4296029-A | Process for preparing hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-10-20 | — | — | US | disclosed |
| EP-0021772-A1 | Method of preparing 2-oxo- and 2-unsubstituted-hexahydroazepine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
| US-4197241-A | Hexahydroazepine, piperidine and pyrrolidine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1980-04-08 | — | — | US | disclosed |
| EP-0003253-A1 | Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for making and using them | JOHN WYETH & BROTHER LIMITED (GB) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.